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Propionibacterium acnes is associated with purulent skin infections, and it poses a global
problem for both patients and doctors. Acne vulgaris (acne) remains a problem due to
its chronic character and difficulty of treatment, as well as its large impact on patients’
quality of life. Due to the chronic course of the disease, treatment is long lasting, and
often ineffective. Currently there are data regarding isolation of P. acnes phages, and
there have been numerous studies on phage killing of P. acnes, but no data are available
on phage application specifically in acne treatment. In this review, we have summarized
the current knowledge on the phages active against P. acnes described so far and their
potential application in the treatment of acne associated with P. acnes. The treatment of
acne with phages may be important in order to reduce the overuse of antibiotics, which
are currently the main acne treatment. However, more detailed studies are first needed to
understand phage functioning in the skin microbiome and the possibility to use phages
to combat P. acnes.
Keywords: Propionibacterium acnes phages, experimental phage therapy, treatment of infections, antibiotic
resistance, topical application
INTRODUCTION
We are entering the post-antibiotic era: infections formerly easy to cure are becoming difficult to
treat, as both increasing frequency of treatment failure and increasing severity of infections have
been observed (Jassim and Limoges, 2014; WHO, 2014). The number of new approved antibiotics
has dramatically decreased, and research on these new drugs is difficult, arduous, and unprofitable
(Clarke, 2003; WHO, 2014).
At present, ∼50 million people in the US are suffering from acne, 85% of whom are at the
age of 12–25 (Sidbury and Paller, 2000; Lynn et al., 2016). Disorders arising as a result of the
reaction to acne can lead to a significant reduction in self-esteem (Sidbury and Paller, 2000). The
inflammatory form of acne may leave scars that can result in permanent disfigurement. Correct
and appropriate use of antibiotics in the treatment of acne will help to preserve their utility in the
face of increasing antibiotic resistance, and therefore greater awareness of the issues is required
among prescribing physicians (Dréno, 2016). The chief problem with antibiotic therapy of acne
is the common tendency to prolonged use and overuse of antibiotics. Therefore, it is necessary
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to treat acne with effective alternatives to commonly used
antibiotics to reduce the likelihood of resistance to this type of
treatment (Walsh et al., 2016) and obtain a highly specific agent to
destroy bacteria effectively. The US National Institutes of Health
(NIH, US) indicates phages to be innovative components that
may be used to combat antibiotic resistance (NIH, 2014).
Detailed understanding and expanded knowledge of the
microbiome, especially that of human skin, may be fundamental
for recognizing skin-associated pathogenesis, especially acne
vulgaris, and finding therapeutic solutions (Marinelli et al., 2012),
e.g., the possibility to develop phage therapy of this disease.
Further and more detailed studies are needed to understand
phages’ function in the skin microbiome and their participation
in resistance gene transfer (Hannigan and Grice, 2013).
PATHOGENESIS AND EPIDEMIOLOGY OF
ACNE
Acne vulgaris is the most common human skin disease (Valente
Duarte de Sousa, 2014). Despite the implementation of new-
generation antibiotics, the disease continues to have a social
dimension. According to previous studies, the skin of teenagers
suffering from acne vulgaris has up to 100-fold higher numbers
of Propionibacterium acnes compared to healthy skin (Leyden
et al., 1975). However, subsequent studies have failed to detect
any significant discrepancies in the number of P. acnes between
patients and controls. The observed levels of P. acnes were
almost identical, but increased levels of S. epidermidis were
observed (Bek-Thomsen et al., 2008). The presence of specific
phylotypes of P. acnes is thought to be associated with the
disease rather than the abundance of P. acnes (Tomida et al.,
2013).
The etiology of acne is multifactorial, but probably the
main agent associated with acne is the bacterium P. acnes.
This pathogen is associated with acne, but the causality of
the disease is not clear, and the exact role of P. acnes in
acne is controversial. Acne is a chronic dermatosis that may
cause lesions observed as papules or nodules (Zaenglein et al.,
2016). The clinical form of acne depends on the interaction of
the following factors: malfunctioning shedding of hair follicle
cells, excessive sebum secretion, colonization of hair follicles
by P. acnes, and individual factors depending on the host
(e.g., the status of the immune system; Sidbury and Paller,
2000). Oversecreted sebum is accumulated under interconnected
keratinocytes which clog the outlet of the sebaceous glands, thus
creating ideal conditions for P. acnes growth. These bacteria
trigger inflammatory infiltration, and the inflammation can
spread to the dermis. A severe form of acne is acne inversa
(also known as hidradenitis suppurativa), a chronic inflammatory
disease which has the most significant impact on patients’ quality
of life among all assessed dermatological diseases (Wollina et al.,
2013). It may be observed especially in patients with altered
immunity with deficiency of antimicrobial protein secretion
(Wolk et al., 2011). Pain is a major symptom of this form of acne.
Treatment is by application of a drug, sometimes even combined
with surgery (Wollina et al., 2013).
Propionibacterium is one of the main components of human
skin microbiota of healthy adults (Human Microbiome Project
Consortium, 2012; Hannigan and Grice, 2013). It predominates
in sebaceous regions and is estimated to represent nearly
90% of the microbiota (Fitz-Gibbon et al., 2013). It is an
opportunistic, Gram-positive, microaerophilic, nonmotile, and
fat splitting bacteria, which—due to its tendency to elicit an
inflammatory response—is thought to be the probable main
cause of acne. The genomes of different P. acnes strains were
found to be of similar sizes, G+C contents, and encode a
similar number of open reading frames (ORFs) (Tomida et al.,
2013). Another sequencing analysis suggested that acquired DNA
sequences of P. acnes and its immune elements were important
in determining the virulence of P. acnes, and these elements
should be the therapeutic target (Fitz-Gibbon et al., 2013).
According to Fitz-Gibbon et al. (2013), genomic comparison
of P. acnes strains indicated that there may be specific genes
that contribute to the pathology of acne. Holland et al. (2010)
reported that P. acnes produces hydrolases likely to be involved
in degrading human tissue components and immunoreactive
adhesins which are expected to play a role in its virulence.
Moreover, factors that have only been suggested to play a part
in P. acnes pathogenesis (there is no experimental evidence) are:
co-hemolytic CAMP factor 5, gehA lipase, putative hemolysin tly,
sialidases, neuraminidases, endoglycoceramidases (Brüggemann,
2005). The facts that P. acnes may persist inside macrophages
(prostate-infiltrating macrophages and the human macrophage
cell line THP-1) and that it survives phagocytosis are very
important for the pathogenesis of other diseases associated with
this pathogen. This phenomenon may be important for P. acnes-
associated inflammatory diseases (Fischer et al., 2013).
CONVENTIONAL TREATMENT OF ACNE
Antibiotics (both oral and topical) have been used as
therapeutics for acne treatment for 40 years. It is estimated
that every year ∼5 million prescriptions of antibiotics for
oral treatment of acne are prescribed (Stern, 2000). In recent
years, topical, enteral, and parenteral antibiotics have been
used. The most commonly used are: nadifloxacin, ofloxacin,
erythromycin, clindamycin hydrochloride, doxycycline,
tetracycline hydrochloride, minocycline, ampicillin, cephalexin,
gentamycin, and trimethoprim-sulfamethoxazole (Nishijima
et al., 1996; Michałek et al., 2015). Currently, experimental trials
are underway on a new generation quinolone—ozenoxacin in
vitro (Choudhury et al., 2011). This quinolone is mainly for
topical administration which is used as effective treatment for
complicated skin and soft-tissue infections. Its mechanism is
based on simultaneous affinity for two enzymes: DNA gyrase
and topoisomerase IV (Karpiuk and Tyski, 2013). Due to the
chronic course of acne vulgaris, treatment is long and often
ineffective. Ozenoxacin application leads to shortened time
of treatment. For the same reason, oral antibiotic therapy is
supported by drugs applied topically, e.g., doxycycline (100
mg), which is administered orally once daily for 12 weeks and
combined additionally with 5% dapsone applied topically twice
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a day (Kircik, 2016). Nagler et al. (2016) reported that the
average duration of antibiotic therapy in acne in some cases
may even exceed 1 year (Nagler et al., 2016). Such prolonged
therapy can be shortened by the addition of isotretinoin
(a 13-cis-retinoic acid which is a non-aromatic retinoid;
Tilles, 2014), whose action is associated with reduction of
sebum production, anti-inflammatory properties, reduction
in P. acnes and an effect on comedogenesis (decreasing
hyperkeratinization; Layton, 2009). Isotretinoin is used to treat
severe and recalcitrant cases of inflammatory acne. This drug
significantly improves the results of acne treatment, but its
application is associated with such adverse side effects as the
ability to cause mental disorders, e.g., depression or suicidal
thoughts, and even incidents of suicide have been reported.
Nevertheless, improvement in mood and an increase in the
quality of patients’ lives after its application have been observed
(Schrom et al., 2016).
Since prolonged antibiotic therapy in acne treatment is
common, antibiotic resistance of P. acnes strains has been
extensively observed (Sardana et al., 2016; Walsh et al., 2016).
In 1976 there were no reports of antibiotic resistance in
Propionibacterium strains (Leyden, 1976). But already 3 years
later bacterial strains isolated from skin of patients with acne
proved to be cross-resistant to erythromycin and clindamycin
in both in vitro and in vivo studies (Crawford et al., 1979).
Scientists and physicians have raised the alarm that an alternative
to topical antibiotics should be found (Dréno, 2016). They
suggest limiting the use of antibiotics, and especially avoiding
their use as monotherapy (Zaenglein et al., 2016). It has
been demonstrated that prolonged use of antibiotics generates
selective pressure to induce antibiotic-resistant bacteria, and it
correlates with the duration of these drugs’ usage. Antibiotic
resistance in these bacteria develops by spontaneous mutation
rather than the horizontal transfer of multiple drug resistance
genetic determinants (Moore and Sauer, 2008; Neely et al.,
2008).
Using antibiotics may be associated with disturbance in
natural microbiota, and it may cause the risk of colonization of
such stains as Streptococcus pyogenes (Levy et al., 2003). Another
danger that may result from application of antibiotics is the
possibility of P. acnes to form an antibiotic-resistant biofilm.
This natural state of bacterial colonization may protect bacteria
against antimicrobials and facilitate bacterial adherence to tissue
(Coenye et al., 2008; Portillo et al., 2013; Dréno, 2016). P. acnes
has been shown visually to exist as biofilms on the skin by Jahns
and Alexeyev (2014), who observed biofilm spreading for 1900
µm in a terminal hair follicle. To obtain the optimal absorption
of e.g., tetracycline, it is recommended to be used on an empty
stomach (Sidbury and Paller, 2000). It may cause an increase in
the risk of occurrence of such adverse effects as gastrointestinal
disorders. Moreover, in the case of women, candidiasis may
develop. Also, acne vulgaris is thought to have an influence on
the incidence of suicidal ideation in acne patients (∼7.1%; Kumar
et al., 2016).
For the topical treatment of acne, antibiotic-containing
creams, gels, solutions, and microemulsions are used (Sidbury
and Paller, 2000).
BACTERIOPHAGES
Bacteriophages are bacterial viruses that naturally control
microbial populations. They can multiply only in bacterial
cells, and therefore may be active at the site of infection,
where pathogenic bacteria are present. It is estimated that in
the biosphere bacteriophages are 10 times more frequent than
bacterial cells (Abedon, 2011). They are commonly found in the
biosphere (Lin et al., 2010; Zhan et al., 2015) and human and
animal organisms (Keller and Traub, 1974; Caroli et al., 1980;
Gantzer et al., 2002; Bachrach et al., 2003; Reyes et al., 2012).
Bacteriophage morphology shows great diversity, and their
classification was traditionally based on the shape of the phage
particle and the type of nucleic acid. However, the similarity
in structure does not determine the biological properties of
bacteriophages. Nowadays the phage classification is mainly
based on DNA sequence identity (Kropin´ski et al., 2016).
Phages are called “living drugs” (Jassim and Limoges, 2014),
and this term reflects the behavior of phages at the infection
site. There are data confirming their efficacy in treating local
and systemic infections caused by antibiotic-resistant bacterial
strains (including those where bacteria resistant to multiple
antibiotics are etiological agents; Biswas et al., 2002; Keen, 2012;
Mie˛dzybrodzki et al., 2012; Chhibber et al., 2013; Borysowski
et al., 2014; Rose et al., 2014; Cao et al., 2015; Sarker et al., 2016).
Phages have features that give them advantages over
antibiotics, e.g., they are specific to their bacterial host
(Ly-Chatain, 2014), which may minimize the probability of
appearance of secondary infection (Golkar et al., 2014), and
they multiply at the site of infection where there are sensitive
bacteria (Loc-Carrillo and Abedon, 2011). The development
of resistance of bacteria to antibiotics does not equate to
simultaneous development of phage resistance in bacteria,
although bacterial resistance to phages may also be observed.
However, phage-resistant mutants that had lost phage receptors
on the cell surface proved to be less pathogenic than phage-
susceptible ones (Capparelli et al., 2010; León and Bastías, 2015).
Phages are commonly found in the biosphere and therefore are
environmentally friendly, because they are natural structures
based on natural selection (Golkar et al., 2014). The isolation
of new phages for therapeutic purposes is an affordable and
rapid process compared to research and development of new
antibiotics (which takes several years and may cost millions
of dollars for clinical trials). Moreover, phage therapy is less
expensive than conventional antibiotic therapy, which has
been demonstrated in the case of patients with staphylococcal
infections (Mie˛dzybrodzki et al., 2007).
Phages are proved to be safe and well tolerated, with few side-
effects and without any toxic effects (Bruttin and Brüssow, 2005;
Borysowski and Górski, 2008; Denou et al., 2009; Mie˛dzybrodzki
et al., 2012; Miernikiewicz et al., 2013; Łusiak-Szelachowska et al.,
2014).
An important aspect from the therapeutic point of view is
the ability of phages to be temperate (e.g., co-exist with their
host, either in a lysogenic, or pseudolysogenic state), as well
as their ability to induce transduction. These processes may
result in gene transfer between bacterial strains, as well as
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antibiotic resistance genes or pathogenicity genes. These factors
are critical for the safety of phage therapy. However, Modi
et al. (2013) based on their research on antibiotic treatment
of mice (ciprofloxacin or ampicillin) suggested that antibiotic
application increased the frequency of phage integration into
the bacterial genome, and enriched the phage metagenome for
stress and niche specific functions, which shaped the phage-
bacterial network to potentiate accessibility of phage genetic
elements. Moreoever, the phage metagenome from mice treated
with antibiotics was enriched with additional functions that may
contribute to metabolism of the host (e.g., ampicillin-treated
mice acquired a broader carbohydrate metabolic pathway).
To take advantage of the maximal phage potential, a
regulatory framework should be established (Jassim and Limoges,
2014). Successful phage therapy requires phages of only proven
lytic activity, whose lifecycle results from the burst size (Mirzaei
and Nilsson, 2015). As mentioned above, especially personalized
phage therapy (tailored therapy) that uses phages adjusted to
specific pathogenic bacteria that are the cause of infection may be
successful (Jassim and Limoges, 2014; Mattila et al., 2015) due to
higher (5–6-fold) success rates (Zhukov-Verezhnikov et al., 1978)
compared to prêt-à-porter preparations. It is proposed to develop
improved methods of administration and new formulations that
reduce the exposure of phage to destructive conditions. As
emphasized by Nilsson (2014), phages intended to be used in
phage therapy need to be well characterized, produced under
appropriate conditions to obtain the required titer, validated,
purified, and approved for clinical use. This will create a chance to
minimize the problem of bacterial resistance to antibiotics. Thus,
it is necessary to conduct phase III clinical trials (Vandenheuvel
et al., 2015).
Table 1 summarizes phage topical application in the therapy
of skin infections. All the described studies (Table 1) concern
infections caused by bacteria other than P. acnes. These findings
show that topical phage therapy in both animals and humans
may be effective, so there are strong indications supporting the
potential of P. acnes phages to also treat acne.
PHAGES ACTIVE AGAINST
PROPIONIBACTERIUM ACNES
Bacteriophages are a viral component of the skin microbiome,
but the knowledge about them in this environment is
scant (Hannigan and Grice, 2013), probably because of
the colonization of a specific ecological niche (anaerobic
microenvironment). Since 1964 it has been known that
bacteriophages are one of the components of the human skin
community (Brzin, 1964). Webster and Cummins reported in
1978 that 18% of P. acnes isolates carried bacteriophages. In
the skin microenvironment where there is a lack of bacteria
other than P. acnes and their phages, P. acnes phages are proved
to be closely related. The characteristics of described P. acnes
bacteriophages are presented in Table 2.
Antibiotic resistance of P. acnes is emerging (Liu et al., 2014).
Liu et al. (2014) isolated a bacterial strain from facial acne (nose
skin) of a patient who had not previously applied an antibiotic
for acne. It was observed that the isolated HL411PA1 strain was
resistant to most antibiotics (including tetracycline, clindamycin,
and erythromycin), which may confirm the presence of antibiotic
resistance.
Liu et al. (2015) hypothesized that bacteriophages may play
an important role in health and disease, because they are the
main component of the human microbiota, and therefore they
can modulate the bacterial community, especially in the case of
human skin. In a pilosebaceous unit of skin it was found that the
ratio between phages and bacteria is approximately 1:120, but it
may vary (Fitz-Gibbon et al., 2013). Liu et al. (2015) analyzed 48
P. acnes phage metagenomes, and, based on this analysis, they
found that human skin is colonizedmost commonly by one strain
(Liu et al., 2015). It was also demonstrated that the transmission
of phages between individuals is possible. Interestingly, phages
active against P. acnes were isolated more frequently from skin
of healthy volunteers than from patients suffering from acne,
which may indicate that the role of phages in human skin is
regulatory. One phage strain may dominate in the P. acnes
phage population. It was also observed that some groups of
tested phages were identified in different people, which may
indicate that there is a pool of phages that may be shared in
the human population. Furthermore, the transmission of skin
phages is likely between closely related people. Based on their
observations, the authors suggested that in designing phage
therapy the composition of individual microbiome structure
should be taken into consideration.
Marinelli et al. (2012) isolated 11 P. acnes phages from
sebaceous follicles of healthy skin. The isolated phages
were highly homogeneous and showed no genetic diversity,
which the authors linked to their unique habitat. The
tested phages had features (lytic lifecycle, lack of lysogeny-
related genes, and the presence of endolysin-encoding
genes) that make them an ideal tool for phage therapy of
acne.
P. ACNES PHAGES’ ABILITY TO KILL THE
HOST STRAIN
The application of bacteriophages in the therapy of acne shows
initial promise in vitro (Neely et al., 2008; Brown et al., 2016).
P. acnes phages from skin of patients suffering from acne have
been isolated by Brown et al. (2016). Phages active against P.
acnes were found in both the gastrointestinal tract and the oral
cavity (Willner et al., 2011; Sharon et al., 2013). The authors
applied in a semi-solid preparation—Cetomacrogol cream, with
concentration of 2.5 × 108 pfu/ml per gram—phages that
remained active for 90 days when the preparation was stored
in a light-protected place at 4◦C (Brown et al., 2016). The non-
ionic cream-based preparation was chosen because it excludes
potential occurrence of interactions of ions with phage particles.
These properties, especially stability and its easy-to-use form,
ensure this preparation’s potential for topical treatment of skin
P. acnes infections. Benefits were observed from using the
cream form, which can reduce the impact of harmful side-
effects that are observed in common therapy of acne. Moreover,
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TABLE 1 | Topical phage therapy of infection.
Pathogen Model Outcome Result of the therapy
Staphylococcus aureus Early studies of the application of
phage therapy in dermatology in 143
patients with purulent skin infections.
Phage application as direct injection into
the wound and surrounding tissue.
The best results were observed in patients with
acute infections of deep skin. In the studied
group of patients successful treatment was
observed in 75%, improvement in 7.7%, and
no effect of the therapy was observed only in
4.9% of the treated patients (Beridze, 1938).
Staphylococcus 55 patients with furunculosis. Oral and local phage administration. In all cases good therapeutic results were
obtained (S´lopek et al., 1987).
Staphylococcus, Pseudomonas,
Klebsiella, Proteus, Escherichia
Studies concerned 31 patients with
suppurative skin infections.
The treatment lasted 2–16 weeks. During the treatment an improvement with
suppression of local inflammation, faster
healing of ulcers, and eradication of bacteria
was observed. Good therapeutic effects were
obtained in the case of 25 patients (16 with
outstanding results, 7 with marked
improvement, and 2 with transient
improvement; Cisło et al., 1987).
Klebsiella pneumoniae B5055 Mouse model of burn wound
infection.
A single dose of topical application of the
Kpn5 phage suspended in 3% hydrogel
(at MOI of 200) used as ointment.
Mice treated with only a single dose of phage
showed a significant reduction in animals’
mortality (66%) compared to the control group
(Kumari et al., 2010).
Staphylococcus aureus,
Pseudomonas aeruginosa,
Acinetobacter baumannii.
Animal models of diabetic cutaneous
wound infection.
Topical administration in combination with
wound debridement
A decrease in bacterial counts and improved
wound healing in a rodent model of
Staphylococcus aureus and Pseudomonas
aeruginosa infections. The therapy was not as
effective against Acinetobacter baumannii.
Bacteriophage treatment may be effective in
resolving chronic infections also when applied
in combination with wound debridement
(Mendes et al., 2013).
Staphylococcus, Streptococcus,
P. aeruginosa
Patients with wounds/ulcers. Local administration of PhagoBioDerm,
which contains ciprofloxacin,
α-chymotrypsin benzocaine, and
bacteriophage based on biodegradable
poly(ester amide)s matrix.
Resulted in healing in the case of 70% of
patients. It was associated with elimination of
and/or reduction in pathogenic bacteria in the
ulcers. This slow-release biopolymer was safe
and of possible benefit in the management of
refractory wounds, and the apparent utility of
bacteriophages was supported in this setting
(Markoishvili et al., 2002).
Prospective, randomized,
double-blind, controlled phase I study
for the safety and efficacy of
treatment of venous leg ulcers was
conducted by the Southwest
Regional Wound Care Centre in
Lubbock, Texas, USA (in 2006–2008).
Once a week for 12 weeks topical
application of a cocktail of 8 lytic
bacteriophages against P. aeruginosa, S.
aureus, and E. coli. (named WPP-201),
developed by Intralytix Inc., USA.
No safety concerns regarding bacteriophage
treatment (Rhoads et al., 2009).
P. aeruginosa Twenty-four patients suffering from
otitis media caused by antibiotic
refractory P. aeruginosa. A
double-blind, placebo-controlled
initial phase I/II clinical trial targeting
chronic external ear infections (in
2006–2007).
Application of bacteriophage mixture
(Biocontrol Ltd., UK)
The results of the treatment of half of them
treated with a single dose of bacteriophage
mixture confirmed that phage administration
was safe. A significant reduction of clinical
symptoms at day 42 in the bacteriophage
treated group was observed (55% of total
clinical score at day zero) compared to the
control group (104%). It was accompanied by a
76% decrease in mean count of bacteria in
samples taken from the patients’ ears 6 weeks
after phage application, whereas in controls a
9% increase was observed (Wright et al., 2009).
E. coli or P. aeruginosa E. coli or P. aeruginosa burn wound
infections. A phase I/II randomized
multi-center clinical trial involving 11
different burn units located in France,
Belgium and Switzerland. This
four-arm study involves 220 patients.
Two topically applied therapeutic phage
cocktails (PP0121 and PP1131)
Its primary endpoint is the time for reduction of
the targeted bacterial load in wound burns with
a specifically designed microbiological
procedure (Gabard et al., 2015).
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TABLE 2 | Described phages that are active against Propionibacterium acnes.
Phage symbol, total
number of isolated
phage strains
Classification in
family
Brief characteristics Host range and specificity of action Possible use in
phage therapy
PA6 Siphoviridae Lytic (lack of lysogeny genes). Phage
isolated from skin scrub wash sample
from patient. Phage produces clear
plaques with turbid centers.
Able to lyse P. acnes strains, but not able
to lyse other strains that are a part of the
skin microbiome: Propionibacterium
granulosum, Propionibacterium avidum,
Staphylococcus epidermidis,
Corynebacterium bovis (Farrar et al.,
2007)
High specificity only
against P. acnes and
lytic life cycle may
predispose to use of
this phage in the
therapy of acne.
PAC1-PAC10 Not done Pseudolysogenic life cycle. Lysis of P. acnes strains, but not lysis of P.
acidipropionici, P. avidum, P.
cyclohexanicum, P. jensenii, P. thoenii, P.
freudenreichii. Narrow lytic spectrum.
In Cetomacrogol cream
aqueous concentration
of phage for potential
application in topical
treatment of acne
(Brown et al., 2016).
Phage isolated from bacteria from skin
swab sample from patient. It did not
contain bacterial virulence factors.
PAD2-PAD48,
PAS2-PAS52
Siphoviridae Presence of pseudolysogeny. Do not
confer superinfection immunity.
Species specific. Only infect P. acnes, not
other strains closely related to
Propionibacterium (Lood et al., 2008).
Probably bad
candidate for phage
therapy.
P1.1, P9.1, P14.4,
P100A, P100D, P100.1,
P101.A, P104.A, P105
Siphoviridae Probably the presence of pseudolysogeny
(lack of lysogeny-related genes) phages.
Isolated from healthy subjects and patients
with acne. Lack of genetic diversity.
Broad range of clinical isolates, phage
immunity if present is connected with the
presence of chromosomally encoded
elements.
Marinelli et al. (2012)
suggested use of
endolysin—
peptidoglycan
hydrolases that are
bacteriophage-
encoded antimicrobial
peptides to treat
bacterial infection.
48 phages, e.g.,
PHL111M01,
PHL071N05,
PHL060L00,
PHL073M02
Siphoviridae Pseudolysogenic and/or life cycle. 21
phages were isolated from patients with
acne, 27 from healthy volunteers. Phages
have limited diversity in genome.
P. acnes strains (including clades IA-1,
IA-2, IB-1, and IB2) were susceptible to
all 15 tested phages. But strains of clade
IB-3, II, II were highly resistant to phages.
Moreover, P. granulosum and P. avidum
were resistant to all tested phages. Two
strains of P. humerusii were susceptible
to all tested phages, one was susceptible
to 10 from 15 phages. Activity of P. acnes
phages includes bacterial strains that are
closely related to Propionibacterium
species.
The authors suggested
that the isolated
phages may be used in
modulation of
Propionibacterium
populations in human
skin (Liu et al., 2015).
9 phages: from P-a-1 to
P-a-9
Not done Lytic phages, lysogenic ones were not
detected. P-a1 to P-a7 were isolated from
plaques on P. acnes lawn, but P-a-8 and
p-a-9 came from sewage.
Both Gram-positive and Gram-negative
strains from genera other than
Propionibacterium were not lysed by
these bacteriophages (Zierdt, 1974).
Bacteriophages were
used to distinguish C.
ances from C. avidium
and C. granulosum.
Lytic life cycle may
predispose to use of
this phage in the
therapy of acne.
15 phages Polyhedral heads with
flexible unsheathed tails
Lysogenic, induced with mitomycin C from
17% of P. acnes strains
Isolated from P. acnes of healthy
individuals. Strains of P. acnes belonging
to serotype I were more susceptible to
phage than those from serotype II
(Webster and Cummins, 1978).
Probably bad
candidate for phage
therapy because of
lysogenic cycle.
12 phages Not done Lysogenic phages. Phages isolated from
skin swab sample from patient.
Phage of varying host range, but none
which lyses all subtypes of P. acnes.
(Neely et al., 2008).
Bad candidate for
phage therapy because
of lysogenic cycle.
the use of Cetomacrogol moisturizing cream may allow the
contact of phage particles—which are pharmaceutically active
components—with skin areas infected with P. acnes, which may
improve the effectiveness of the suggested therapy. In this study
it was found that the cocktail of phages did not result in higher
inhibition of bacteria when compared to application of a single
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phage, but due to the potential reduction of bacterial resistance,
its use was recommended.
It was demonstrated that phages may be formulated in
a cream (O’Flaherty et al., 2005), as well as in a water-oil
nanoemulsion (Esteban et al., 2014). The latter formulation—
bacteriophage containing a nanoemulsion—caused bacteria
eradication in vivo 10 days after preparation. Markoishvili et al.
(2002) reported application of PhagoBioDerm, which contains
ciprofloxacin, α-chymotrypsin benzocaine, and bacteriophage
based on a biodegradable poly(ester amide)s matrix in patients
with wounds/ulcers. Phage application was also demonstrated in
humans using an antiseptic gel and paraffin-oil-based lotion to
destroy Acinetobacter baumannii (Chen et al., 2013).
The treatment of acne with phages in different types of
formulations, e.g., creams or liquids, may be important in
reducing the overuse of antibiotics, which is the primary means
of acne treatment.
APPLICATION OF ENZYMES ENCODED IN
PHAGE GENOME AND PHAGE
MODIFICATION
Marinelli et al. (2012) found in phage genomes regions that
encode phage endolysin, which is conserved in all tested P. acnes
phages. These enzymes probably bind to essential elements of
the P. acnes cell wall and may kill a broad range of P. acnes
strains. They are essential proteins for the release of progeny,
causing lysis of the host bacteria. The authors suggested that
it may be possible to develop topical treatment of acne by the
use of P. acnes-encoded endolysins. They are enzymes encoded
in the bacteriophage genome with the ability to cause lysis
of the bacterial cell wall peptidoglycan during the phage lytic
cycle (Tišáková and Godány, 2014). The enzymes may create
opportunities for the construction of genetically engineered
enzymes for bacteria elimination, as well as experimental
therapies. The detected endolysins in all the characterized P.
acnes phages were found to be over 95% conserved at the
amino acid level (Marinelli et al., 2012). This feature creates
the possibility to use any endolysin successfully, destroying
every P. acnes strain. Moreover, resistance to endolysins has
not been observed so far (Nelson et al., 2012). The use
of phage lysins as treatment against bacterial infections was
demonstrated both in vitro and in vivo. The PlyG endolysin
isolated from the γ phage was applied against B. anthracis by
Schuch et al. (2002). Susceptibility of B. anthracis strains to
the purified PlyG lysin indicated that this agent has a narrow
bacteriolytic spectrum—especially with high activity against only
B. anthracis strains. In bacterial culture, application of lysin
caused morphological changes of bacterial cells and led to
cell lysis. BALB/c mice were intraperitoneally infected with
streptomycin-resistant B. cereus RSVF1 (with the same proven
lytic activity of lysin as in the case of B. anthracis strains) and
15min later were treated with 50 and 150 U of PlyG. The
application of lysin significantly rescued mice in comparison
to untreated animals. Bacterial resistance to PlyG was not
observed in vitro, and the authors demonstrated that the RSVF1
strain that became resistant to the phage remained sensitive to
PlyG.
Recently, we have suggested that phages armed with homing
peptides should allow for their better tissue penetration
and achieving in situ concentrations necessary for successful
eradication of infection and control of inflammation (Górski
et al., 2015). This methodology may also be relevant for phage
treatment of infections associated with P. acnes.
Another approach suggests that phages may be used to
improve antibiotic efficacy; in particular, phages may be a tool
used for sensitizing antibiotic-resistant bacteria by introducing
sensitivity genes (e.g., rpsL ayrA) to bacteria, which may restore
drug efficacy (Wikoff et al., 2000; Salmond and Fineran, 2015).
The authors believe that antibiotics conjugated with phages may
enable the delivery of the drug to target cells and increase the
concentration of the drug at the site of infection (Salmond
and Fineran, 2015). The issue of a combined treatment with
phages and antibiotics has recently been addressed in some
detail by Torres-Barceló andHochberg (2016). This approach has
been recommended by some authors (e.g., Chanishvili, 2016).
However, we need more data to establish the real value of such
therapy, and one should also note that the emergence of double-
resistant phage mutants poses a potential threat (Torres-Barceló
and Hochberg, 2016).
LIMITATIONS OF PHAGE USE FOR
ELIMINATION OF P. ACNES
Bacteria have an adaptive immune system which is based
on a region of DNA called Clustered Regularly Interspaced
Short Palindromic Repeats (CRISPR) and CRISPR-associated
(cas) genes separated by short sequences (Rath et al., 2015;
Maxwell, 2016). This system protects bacteria against viruses and
other mobile genetic elements. It may be responsible for phage
resistance in bacteria. Also P. acnes proved to have CRISPR
elements, and its role in the phage resistance results from the
correlation between these elements and spacer matches with the
phage genomes, as suggested by Marinelli et al. (2012). This
system, which has also been found in P. acnes, may cause phage
ineffectiveness (Brüggemann and Lood, 2013).
Another limitation associated with the application of P. acnes
phages is the high homogeneity within P. acnes phages, which
may be beneficial with the use of phage formulations of broad
activity and application of available ready to use phages of
limited activity, avoiding phage typing. However, acquisition
of resistance to one phage may result in resistance to others
(Brüggemann and Lood, 2013). The effect of P. acnes phages’
homogeneity may limit the efficacy of the phage therapy.
The term “pseudolysogeny” for P. acnes phages was first
mentioned in 2011 by Lood and Collin (2011). Probably
most, if not all, P. acnes phages characterized to date display
pseudolysogeny (Farrar et al., 2007; Lood et al., 2008; Lood, 2011;
Marinelli et al., 2012) and form turbid plaques. Pseudolysogeny
is an unstable state in which the phage genome is not integrated
into the bacterial genome (Lood and Collin, 2011). Without cell
lysis, the phage genome exists in the host cell as an episome,
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with superinfection immunity of bacteria from phage infection,
and phage DNA exists as a subpopulation. Both the lysogenic
and pseudolysogenic cycle do not cause direct lysis of bacteria,
or may lead to phage resistance, and these phenomena are not
beneficial from the therapeutic point of view. Phages specifically
active against P. acnes strains may shape the skin microbiome
composition and influence the health-disease balance. Moreover,
they do not integrate into the host chromosome and transfer
bacterial pathogenicity genes, which is an advantage in their use
as therapeutics.
There are no data in the available literature regarding
phage application against skin infections caused by P. acnes
in an animal model, while the results obtained in vitro
do not necessarily translate into the situation in vivo. This
situation does not facilitate prompt clinical application of phages.
On the other hand, phages intended for topical use in the
treatment of acne could be used as a medical application
which could make the process of their registration more
straightforward.
The potential of phage therapy in the treatment of acne has
been highlighted by a recent article that emphasized the need
for more prudent use of antibiotics in this condition, as well
as an urgent need to search for alternative treatments. The
authors also draw attention to the changing concept of acne,
where inflammation appears to play a prominent role in its
pathology. This constitutes another strong argument for the
potential application of phages in acne, as the anti-inflammatory
action of phage therapy is well documented (Górski et al., 2012).
CONCLUDING REMARKS
Phage therapy offers a real chance for patients suffering from
chronic infections caused by antibiotic-resistant bacteria. This
therapy may replace or supplement conventional antibiotic
therapy, help eliminate antibiotic resistance of bacterial strains,
and eliminate deleterious effects of chemical antibiotics.
There is a need to develop phage therapy of acne, but
more research is needed to understand bacteria-bacteriophage
interactions in the skin community to obtain comprehensive
knowledge on how to use phages to combat P. acnes when
it becomes pathogenic (in the pathogenesis of acne vulgaris).
Phages should gain acceptance and be widespread as an antibiotic
supplement or an alternative in the treatment of infections caused
by antibiotic-resistant bacteria, including those whose etiological
agent is P. acnes. There are also some limitations of the potential
application of anti-P. acnes phages. Those include their high
homogeneity which may cause difficulties in identifying other
phages if phage resistance develops. In addition, the lack of data
on phage application in skin infections caused by P. acnes may
delay such clinical application.
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